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PREFACE 
 
On account of the affluence and medical advances of developed countries, we 
now have an average life expectancy of 80 years. Then, the risk of various diseases such 
as cancers, cardiac disorders, apoplexy, and diabetes increases. Meanwhile, infectious 
diseases have been a threat to all mankind regardless of age and sex since time began. 
Influenza is one of the most familiar infectious diseases. It is a respiratory disorder caused 
by influenza viruses. Influenza can cause severe clinical symptoms compared with other 
respiratory infectious diseases, and it is highly contagious. Accordingly, the influenza 
virus is a considerable burden on medical and public health worldwide. 
Influenza viruses belong to the Orthomyxoviridae family and possess eight 
segments of negative-stranded viral RNA (vRNA). They are classified into three major 
types, influenza A, B, and C viruses, based on the antigenicities of their internal proteins 
(Wright et al., 2013). Influenza A and B viruses have been circulating in humans. Because 
influenza A viruses have the potential to cause pandemics, these viruses have been 
extensively studied from global surveillance to their interactions with host cell systems. 
Influenza A viruses are further classified into subtypes based on the 
antigenicities of their two surface proteins, hemagglutinin (HA) and neuraminidase (NA). 
Currently, 18 HA and 9 NA subtypes have been identified (Tong et al., 2012; Tong et al., 
2013; Wright et al., 2013). During the 20th century, we experienced three pandemics 
caused by influenza A virus: Spanish influenza in 1918 (H1N1 subtype), Asian influenza 
in 1957 (H2N2 subtype), and Hong Kong influenza in 1968 (H3N2 subtype). Although 
the origin of the Spanish influenza remains controversial, the H2 HA, N2 NA, and PB1 
gene segments of the Asian influenza and the H3 HA and PB1 gene segments of the Hong 
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Kong influenza came from avian influenza viruses (Scholtissek et al., 1978; Kawaoka et 
al., 1989). In 2009, the newly emerging swine origin influenza A virus (H1N1) rapidly 
spread all over the world and resulted in the first pandemic of this century. The World 
Health Organization (WHO) defined this virus as A(H1N1) pdm09. At that time, a triple 
reassortant virus between human H3N2, North American avian, and classical swine 
viruses was circulating in the North American pig population. A(H1N1) pdm09 emerged 
by further reassortment of the triple reassortant virus with a Eurasian avian-like swine 
virus (Dawood et al., 2009; Smith et al., 2009). Thus, newly emerging viruses that result 
from the reassortment of viral gene segments derived from distinct viruses circulating in 
various animals can occasionally cause pandemics. This is a key characteristic of 
influenza viruses. 
 Since the first case of human infection with an H5N1 highly pathogenic avian 
influenza virus was identified in Hong Kong in 1997 (Claas et al., 1998), H5N1 viruses 
have undergone rigorous surveillance. Avian influenza viruses are thought to have a low 
probability of airborne human-to-human transmission due, in part, to the difference in 
receptor binding preference between human and avian viruses (Rogers et al., 1983); 
indeed, only sporadic cases of infection have been reported. Nevertheless, the case fatality 
rate of infection with H5N1 highly pathogenic avian influenza viruses is estimated to be 
~60%. Therefore, a pandemic caused by one of these viruses would inflict enormous 
damage on human society. Recently, several mutations in H5 HA that allow transmission 
between mammals via the airborne route were identified in a ferret model (Herfst et al., 
2012; Imai et al., 2012). Importantly, H5N1 avian influenza viruses that possess some of 
these mutations have been isolated in nature (Neumann et al., 2012).  
 In addition to H5N1 subtypes, H7N9 avian influenza virus infection of humans 
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was reported in China in 2013 (Chen et al., 2013; Gao et al., 2013; Li et al., 2013). Because 
viruses of the H7N9 subtype have not previously circulated in humans, no one has specific 
immunity against these viruses (Watanabe et al., 2013). To make matters worse, limited 
transmissibility of H7N9 viruses isolated from human patients was observed in a ferret 
model (Belser et al., 2013; Richard et al., 2013; Watanabe et al., 2013). If influenza 
viruses we have never encountered acquire the ability to transmit more readily via the 
airborne route from person to person, it is highly likely that such viruses will cause a 
pandemic. It is difficult to predict which subtype of virus will cause a pandemic; therefore, 
we have to continue the global surveillance and basic research of influenza viruses. 
 Influenza viruses infect the respiratory tract. Avian influenza viruses 
preferentially recognize 2,3-linked sialic acid (SA) and human isolates recognize 2,6-
linked SA as receptors (Rogers et al., 1983). After binding and internalization, viruses are 
transported via the endocytosis pathway (Matlin et al., 1981; Sieczkarski et al., 2002), 
and then viral RNAs (vRNAs) are released from virions after virus-host membrane fusion. 
During the influenza virus replication cycle, vRNAs are sensed by pattern recognition 
receptors (PRRs), such as retinoic acid inducible gene-I (RIG-I) (Hornung et al., 2004; 
Pichlmair et al., 2004) and toll-like receptor (TLR) 7 (Diebold et al., 2004), and 
subsequent antiviral responses, including the production of type I interferon, pro-
inflammatory cytokines, and chemokines, are elicited (Kawai et al., 2006). Then, various 
immune cells such as monocytes and neutrophils infiltrate the sites of infection depending 
on the secreted chemokines to contain the spread of virus and remove the virus-infected 
cells. The inflammatory responses then resolve due to the action of anti-inflammatory 
cytokines such as interleukin (IL)-10, and adaptive immunity, which is dominated by T 
cells and B cells, is activated. In this doctoral thesis, I focused on three points: (1) 
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influenza virus infection within host cells and the induction of antiviral responses in vivo, 
(2) the resolution of inflammation, and (3) the induction of virus-specific adaptive 
immunity. 
 Little is known about how an influenza virus infection spreads throughout the 
body over time due to the lack of a suitable reporter virus that would allow us to detect 
virus-infected cells easily in the body. It is difficult to stably express a foreign gene 
because the size of the viral genome is limited and the mechanisms for incorporation of 
segmented viral genomes into virions are not fully understood. In 2010, a replication-
competent recombinant virus that expressed green fluorescent protein (GFP) in infected 
cells was reported (Manicassamy et al., 2010). This reporter virus was very useful, but 
had several problems in terms of stability of GFP expression. For these reasons, our group 
improved the expression of the fluorescent protein in this reporter virus. In chapter I, I 
will describe the characterization of the improved reporter virus and my analysis of the 
host responses obtained when using this reporter virus.   
 To prevent infection with influenza viruses, vaccination is one of the most 
effective measures. Two types of influenza vaccines are available, inactivated vaccines 
and live attenuated vaccines; however, there is still room for improvement in terms of 
their immunogenicity and safety, respectively (Cox et al., 2004). In chapter II, I show the 
results of my assessment of the efficacy of a new vaccine based on a replication-
incompetent virus. Specifically, I generated a replication-incompetent virus that was 
deficient in HA membrane fusion activity and assessed its vaccine efficacy.  
 In chapter III, I attempted to develop a bivalent vaccine based on a replication-
incompetent virus that carried an antigen for another respiratory infectious agent, 
Streptococcus pneumoniae. I selected S. pneumoniae because it is a causative agent of 
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not only community-acquired pneumonia but also a bacterial pneumonia that follows 
influenza virus infection (Morens et al., 2008; Jambo et al., 2010; Gill et al., 2010). I 
generated a virus that expresses pneumococcal surface protein A (PspA) in infected cells, 
and then assessed its vaccine efficacy in mice. I conclude my thesis by suggesting new 
possibilities for replication-incompetent viruses. 
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Chapter Iは雑誌掲載のため公表できません。 
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Abstract 
 
Vaccination is one of the most effective measures to protect against influenza 
virus infection. Inactivated and live-attenuated influenza vaccines are available; however, 
their efficacy is suboptimal. To develop a safe and more immunogenic vaccine, I 
produced a novel replication-incompetent influenza virus that possesses uncleavable 
hemagglutinin (HA) and tested its vaccine potential. The uncleavable HA was engineered 
by substituting the arginine at the C-terminus of HA1 with threonine, which prevents 
cleavage of HA into its HA1 and HA2 subunits, preventing fusion between the host and 
viral membranes. Although this fusion-deficient HA influenza virus that possesses 
uncleavable HA (uncleavable HA virus) could undergo multiple cycles of replication in 
only wild-type HA-expressing cells, it could infect normal cells and express viral proteins 
in infected cells, but could not generate infectious virus from infected cells due to the 
uncleavable HA. When C57BL/6 mice were intranasally immunized with the uncleavable 
HA virus, influenza-specific IgG and IgA antibodies were detected in nasal wash and 
bronchoalveolar lavage samples and in serum. In addition, influenza-specific CD8+ T 
cells accumulated in the lungs of these mice. Moreover, mice immunized with the 
uncleavable HA virus were protected against a challenge of lethal doses of influenza virus, 
unlike mice immunized with a formalin-inactivated virus. These findings demonstrate 
that this fusion-deficient virus, which possesses uncleavable HA, is a suitable influenza 
vaccine candidate. 
 
 
10 
 
Introduction 
        
Influenza viruses cause acute respiratory disease and are responsible for 
epidemics and occasional pandemics as exemplified in 2009 (Dawood et al., 2009; 
Neumann et al., 2009). Although medical treatment options are well developed, influenza 
continues to be a great burden on public health and economies worldwide. 
       Currently, inactivated and live-attenuated vaccines are available. While 
inactivated vaccines are safe and induce virus-specific immunoglobulin G (IgG) in sera 
because of intramuscular administration, live-attenuated vaccines, which bear introduced 
mutations that are responsible for temperature sensitivity and viral attenuation (Maassab 
et al., 1968; Chen et al., 2006; Hoffmann et al., 2005; Jin et al., 2003; Jin et al., 2004), are 
more effective because they induce not only virus-specific IgG but also secretory 
Immunoglobulin A (IgA) at the site of infection following intranasal administration (Cox 
et al., 2004). In addition to inducing antibodies, live-attenuated vaccines elicit the virus-
specific cytotoxic T lymphocytes (CTLs). CTLs specifically lyse infected cells and 
prevent viral spread. CTLs are also known to have cross-reactivity between different 
subtypes of influenza A virus. Thus, the induction of CTLs has attracted attention in 
vaccine development (Rimmelzwaan et al., 2007). Nevertheless adverse effects, such as 
runny nose, due to replication of the live-attenuated vaccine virus are an issue (Ambrose 
et al., 2008), and importantly, this live vaccine is not recommended for children under the 
age of 2, adults aged 50 or over, pregnant women, or immunocompromised patients (Fiore 
et al., 2010). To overcome current limitations, an ideal influenza vaccine continues to be 
sought and various strategies have been employed such as virus-like particles (VLPs) 
(Lambert et al., 2010). 
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       To develop a safe and more effective vaccine that has the merits of inactivated 
and live-attenuated vaccines, we previously proposed a replication-incompetent virus as 
a novel influenza vaccine. We reported that NS2-knockout VLPs could efficiently protect 
mice against lethal doses of influenza virus (Watanabe et al., 2002). However, because of 
the lack of a cell line that stably expresses NS2 protein, we have to generate VLPs by 
transfecting plasmids each time.  
To overcome this drawback, here I developed a novel replication-incompetent 
virus that possesses an uncleavable HA (uncleavable HA virus) and assessed its 
immunogenicity and vaccine efficacy in mice.
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Materials and methods 
 
Plasmids. To generate the construct encoding the uncleavable HA gene, we used 
a plasmid containing the HA gene of A/California/04/09 (CA04) as a template for PCR 
and primers containing nucleotide replacements at positions 1031 and 1032 of the HA 
gene, which introduce amino acid substitutions at the cleavage site of HA. This mutated 
HA gene was cloned into a plasmid under the control of the human polymerase I promoter 
and the mouse RNA polymerase I terminator (referred as PolI plasmid) as described 
previously (Neumann et al., 1999). In addition, a plasmid for the expression of wild-type 
CA04 HA was also constructed by cloning the open reading frame of the CA04 HA gene 
into an expression plasmid pCAGGS (Niwa et al., 1991). 
 
Cells and viruses. Madin-Darby canine kidney (MDCK) and human embryonic 
kidney 293T (HEK293T) cells were maintained in minimum essential medium (MEM) 
containing 5% of newborn calf serum (NCS) and in Dulbecco’s modified Eagle medium 
supplemented with 10% fetal calf serum, respectively. MDCK cells expressing HA from 
CA04 [HA-MDCK (CA04)] and from A/WSN/33 (WSN) [HA-MDCK (WSN)] were 
established as follows: for HA-MDCK (CA04) cells, MDCK cells were co-transfected 
with plasmids for the expression of CA04-HA and puromycin N-acetyltransferase, and 
were cultured in MEM containing 5% NCS and 5 g/ml puromycin dihydrochloride 
(Nacalai Tesque). Expression of HA in selected cell clones was confirmed by means of 
immunostaining with an anti-CA04 HA antibody. For HA-MDCK (WSN), MDCK cells 
were transfected with plasmids expressing WSN-HA and WSN-neuraminidase (NA) 
along with pcDNA3.1(+) (Invitrogen), and were cultured in MEM containing 5% NCS 
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and 0.8 mg/ml Geneticin. Surviving cell colonies were picked and were tested for HA and 
NA expression by means of immunostaining with anti-WSN HA and NA antibodies. 
Antigen-positive cells were then cloned by using a limited dilution assay. Expression of 
HA but not NA protein was confirmed in the resulting cell clones. All cells were 
maintained at 37°C in 5% CO2. Mouse-adapted CA04 virus (Sakabe et al., 2011) was 
propagated in MDCK cells as previously described. 
 
Generation of uncleavable HA virus. The uncleavable HA virus was artificially 
generated by using plasmid-based reverse genetics as described previously (Neumann et 
al., 1999). This virus was a reassortant between CA04 and A/Puerto Rico/8/34 (PR8) 
viruses. Briefly, eight PolI plasmids (mutant HA and NA (Sakabe et al., 2011) from CA04 
and all others from PR8 (Horimoto et al., 2007) were transfected with five protein-
expressing plasmids for the expression of the three polymerases, nucleoprotein (NP) 
(Horimoto et al., 2007), and wild-type CA04 HA into HEK293T cells. Forty-eight hours 
after transfection, the supernatants containing the uncleavable HA virus were harvested 
and propagated once in HA-MDCK (CA04) at a multiplicity of infection (MOI) of 0.001 
at 35°C for 48 h in MEM containing L-(tosylamido-2-phenyl) ethyl chloromethyl ketone-
treated trypsin (0.8 g/ml) and 0.3% bovine serum albumin (BSA) (Sigma Aldrich). Cell 
debris was removed by centrifugation at 3,500 rpm for 20 min at 4°C and the supernatants 
were stored at -80°C until use. 
 
Preparation of formalin-inactivated virus. For the formalin-inactivated virus, 
a reassortant virus between CA04 (wild-type HA and NA genes) and PR8 (the rest of the 
genes) (CA04 2:6 virus) was generated by using plasmid-based reverse genetics as 
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described above. The virus was propagated in MDCK cells and the culture supernatants 
containing the virus were treated with 0.1% formalin (final concentration) (Sigma 
Aldrich) at 4C for a week to inactivate infectivity. Inactivation of the virus was 
confirmed by the absence of detectable infectious virus following inoculation of formalin-
treated virus into MDCK cells. After confirmation of inactivation of infectivity, formalin-
treated virus was purified by sucrose-gradient ultracentrifugation at 100,000 g for 2 h 
at 4C and stored at -80C until use. 
 
Immunostaining assay. Twenty-four hours after infection with viruses, cells 
were washed twice with phosphate-buffer saline (PBS) and fixed with 100% methanol 
for 30 min at room temperature. To detect CA04 HA-expressing cells, these cells were 
reacted with anti-CA04-HA antibody. To determine the viral titer of the uncleavable HA 
virus, we conducted the same procedure after performing a plaque assay with HA-MDCK 
(WSN) cells.  
 
Immunization and protection test. Four-, six-, or eight-week-old female 
C57BL/6 mice (Japan SLC) were intranasally immunized with 50 l of 1.7 x 105 PFU 
(equivalent to 16 hemagglutination units (HAU)) of the uncleavable HA virus three times, 
twice, or once, respectively, at 2-week intervals. As control groups, female C57BL/6 mice 
(4-week-old) were intranasally immunized with 50 l of 16 HAU of the formalin-
inactivated virus (FI) or with medium three times at 2-week intervals. Three weeks after 
the final vaccination, six mice per group were euthanized to obtain sera, bronchoalveolar 
lavage (BAL), and nasal washes. In addition, three mice per group were euthanized to 
obtain lungs and spleen for detection of viral-specific CD8+ T-lymphocytes. Also three 
15 
 
weeks after the final vaccination, mice were challenged with 10 or 100 times the 50% 
mouse lethal dose (MLD50) of mouse-adapted CA04 virus. Eight mice per group were 
monitored for survival and body weight changes for 14 days after challenge. Lungs and 
nasal turbinates from three mice per each group were collected on days 3 and 6 after 
challenge to determine virus titers. Virus titers were determined on MDCK cells.  
 
Detection of virus-specific antibodies. Virus-specific antibodies in nasal wash, 
BAL, and serum were detected by using an enzyme-linked immunosorbent assay 
(ELISA) (Kida et al., 1982). I used undiluted samples (nasal washes and BAL) and 1:10 
diluted samples (serum). In this assay, 96-well ELISA plate wells were coated with 
approximately 200 HAU (in 50 l) of purified CA04 virus treated with disruption buffer 
(0.5M Tris-HCl [pH 8.0], 0.6M KCl, and 0.5% Triton X-100). After incubation of the 
samples on virus-coated plates, goat anti-mouse IgA or IgG antibody conjugated to 
horseradish peroxidase (Kirkegaard & Perry Laboratory Inc) was added to detect bound 
antibody. 
 
Detection of virus-specific CD8+ T lymphocytes. A tetramer assay was used to 
detect virus-specific CD8+ T lymphocytes. Single cell suspensions of lung and spleen 
were prepared from inoculated mice three weeks after their final vaccination. After being 
incubated with anti-CD16/32 (BD Bioscience), the cells were mixed with a Phycoerythrin 
(PE)-conjugated H-2Db tetramer specific to the NP epitope (amino acid positions 366–
374, ASNENMETM) (MBL) at room temperature for 20 min. Cells were then incubated 
with Allophycocyanin-cyanine 7 (cy7)-conjugated anti-CD3 antibody (BD-Bioscience), 
PE-cy7-conjugated anti-CD8 antibody (BD Bioscience), and via-probe (BD Bioscience) 
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for 30 min at 4C and then washed with PBS containing 0.5% BSA and 2 mM EDTA (pH 
7.2). Cells were analyzed with FACSAria II (Becton, Dickinson and Company) and 
FlowJo software (Tree Star, Inc.). 
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Results 
 
Replicative ability and viral protein expression of the uncleavable HA virus 
in vitro.        To generate the uncleavable HA, the arginine at the cleavage site of 
HA1, which is important for HA cleavage by trypsin-like protease, was changed to 
threonine. Since the cleavage of HA protein is essential for membrane fusion (Skehel et 
al., 2000), a virus possessing this uncleavable HA should be unable to complete its 
replication cycle. To assess this, I examined if the uncleavable HA virus replicated in 
MDCK and HA-MDCK (CA04) cells: the latter cells constitutively express CA04 virus 
HA. As expected, CA04 2:6 reassortant virus, serving as a control, replicated to a similar 
extent in both MDCK and HA-MDCK (CA04) cells (Fig. 1). By contrast, although no 
infectious particles of the uncleavable HA virus were detected in the supernatant of 
MDCK cells, the uncleavable HA virus could replicate efficiently in HA-MDCK (CA04) 
cells, to a level comparable to that of CA04 2:6 reassortant virus (Fig. 1). I also tested 
whether the virus could revert to the wild-type by passaging it in MDCK cells. After three 
passages, I did not observe any cytopathic effect (data not shown), suggesting that the 
mutation was stable.  
To further ensure that the uncleavable HA virus replicated in HA-MDCK cells, 
but not in MDCK cells, I visualized the infected cells by immunostaining (Fig. 2). 
Whereas CA04 2:6 virus efficiently spread in both cell types (Fig. 2, left panels), the 
uncleavable HA virus only infected and expressed viral protein (HA in this case) in 
individual MDCK cells (Fig. 2, upper middle panel) although it efficiently spread in HA-
MDCK (WSN) cells (Fig. 2, lower middle panel). These results indicate that the 
uncleavable HA virus is replication-incompetent, capable of only a single cycle of  
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Fig. 1. Growth kinetics of CA04 2:6 and uncleavable HA viruses in MDCK and HA-
MDCK cells. 
 Both cell types were infected with viruses at an MOI of 0.001. Supernatant was collected 
every 12 h, and viral titers in the supernatants of both cell types were determined by means 
of the conventional plaque assay or a plaque assay with immunostaining with an anti-HA 
antibody using HA-MDCK cells. The broken line indicates the detection limit for virus 
titers (5 PFU/ml).  
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Fig. 2. HA protein expression in virus-infected cells.  
MDCK and HA-MDCK (WSN) cells were infected with CA04 2:6 and uncleavable HA 
viruses; 24 h after infection, the cells were fixed and stained by using an anti-CA04 HA 
antibody. Cells colored brown are CA04 HA-expressing cells. 
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infection and unable to produce infectious progeny in normal MDCK cells. 
 
Induction of virus-specific immunity by the uncleavable HA virus in mice. 
To assess the ability of the uncleavable HA virus to induce virus-specific immunity 
against influenza virus, I immunized mice with the uncleavable HA virus or FI. To 
examine virus-specific antibody production, IgG and IgA against CA04 in the nasal wash, 
BAL, and serum of immunized mice were measured by using an ELISA (Fig. 3). 
Although only low levels of antibodies were detected in mice immunized three times with 
FI or inoculated with medium, antibody levels increased as the number of vaccinations 
increased in mice immunized with the uncleavable HA virus. Notably, both the virus-
specific IgG and IgA titers in BAL, and the IgG in serum from mice immunized only once 
with the uncleavable HA virus were higher than the respective titers from mice 
immunized with FI three times.  
       I also examined the virus-specific (NP in this case) CD8+ T cell response by 
using a tetramer assay. NP-specific CD8+ T cells were identified in the lungs and spleens 
only of mice immunized with the uncleavable HA virus (Fig 4). Of note, NP-specific 
CD8+ T cells predominantly accumulated in the lungs rather than the spleens of the 
immunized mice (Fig. 4), and the number of NP-specific CD8+ T cells increased as the 
number of vaccinations increased (Fig. 4B). 
These results demonstrate that the uncleavable HA virus could elicit both 
humoral and cellular immunity more efficiently than FI against influenza virus at the local 
sites where influenza virus replicates. 
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Fig. 3. Induction of virus-specific IgG and IgA in nasal wash, BAL, and serum of 
mice immunized with the uncleavable HA virus.  
Virus-specific antibodies were detected by means of an ELISA. Samples from six mice 
from each group were obtained 3 weeks after the final vaccination. Results are expressed 
as the mean absorbance (± standard deviations) of undiluted samples (nasal wash and 
BAL) or of 1:10 diluted samples (serum). Statistically significant differences among the 
groups were assessed by using the Tukey-Kramer method. Asterisks (* or **) indicate a 
significant difference from samples from mice inoculated with FI (*, P<0.05; **, P<0.01). 
The numbers on the x-axis indicate the times of vaccination of uncleavable HA virus. M: 
medium. FI: Mice were immunized with formalin-inactivated vaccine three times with 2 
week intervals. 
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Fig. 4. Induction of virus-specific CD8+ T cells in mice immunized with the 
uncleavable HA virus. 
Virus-specific CD8+ T cells were detected in the lungs and spleen of inoculated mice by 
using a tetramer assay. (A) Representative dot plot for CD3 CD8cells from the 
spleen or lungs of a mouse inoculated with medium or with the uncleavable HA virus. 
(B) The percentage of virus-specific CD8+ T cells (NP-tetramer+ CD8+ population) in 
the CD3 CD8cell populations in the lungs and spleen of inoculated mice. Results are 
expressed as the mean values ( ±  standard deviations). Statistically significant 
differences among the groups were assessed by using the Tukey-Kramer method. 
Asterisks (* or **) indicate significant differences from samples from mice inoculated 
with FI (*, P<0.05; **, P<0.01). 
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Protection against influenza virus in mice immunized with the uncleavable 
HA virus. Finally, I evaluated the protective ability of the uncleavable HA virus. To this 
end, I monitored body weight changes and survival of mice immunized with the 
uncleavable HA virus after challenge. The body weights of mice inoculated with medium 
decreased rapidly to approximately 70%–80% (Fig. 5A) and most mice (7 out of 8) 
succumbed to their infection (Fig. 5B). The body weights of mice immunized with FI also 
clearly decreased to 80% (Fig. 5A) and several mice (3 and 5 out of 8 with 10 and 100 
MLD50, respectively) died (Fig 5B). By contrast, with 10 MLD50, mice immunized once 
with the uncleavable HA virus showed slightly reduced body weights, and mice 
immunized twice and three times with this virus showed no body weight changes (Fig. 
5A left panel). Moreover, all mice immunized with this virus survived (Fig. 5B left panel). 
With 100 MLD50, although mice immunized once with this virus showed similar body 
weight reductions as mice immunized with medium and FI, the mice immunized twice 
and three times with the uncleavable HA virus showed only slight or no body weight loss, 
respectively (Fig. 5A, right panel). All mice immunized with the uncleavable HA virus 
survived, except for 3 out of 8 mice immunized only once with the uncleavable HA virus 
(Fig. 5B, right panel).  
I also determined virus titers in the lungs and nasal turbinates of mice immunized 
with the uncleavable HA virus after challenge (Table 1). Virus titers in both organs of 
mice immunized with the uncleavable HA virus were appreciably lower as the number of 
vaccinations increased, especially on day 6 post-infection, than those in organs of mice 
immunized with medium or with FI. Taken together, these results indicate that the 
uncleavable HA virus has potency as an influenza vaccine. 
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Fig. 5. Body weight changes and survival curves for mice challenged with wild-type 
virus.  
Eight mice per group were intranasally challenged with 10 or 100 MLD50 of mouse-
adapted CA04 3 weeks after the final vaccination. Body weights were measured (A) and 
survival rate was monitored (B) for 14 days after challenge. 
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Table. 1. Protection against challenge with lethal doses of influenza virus in mice 
immunized with an uncleavable HA virusa  
                     
challenge 
dose 
inoculum 
days post- 
infection 
organ 
Virus titer (mean 
±SD log10[PFU/g]) 
 
challenge 
dose 
inoculum 
days post- 
infection 
organ 
Virus titer (mean 
±SD log10[PFU/g]) 
10MLD50 Medium 3 dpi NTb 5.1 ± 0.6  100MLD50 Medium 3 dpi NT 5.7 ± 0.4 
   Lung 7.0 ± 0.4     Lung 7.5 ± 0.2 
  6 dpi NT 4.2 ± 0.3    6 dpi NT NAc 
     Lung 6.4 ±0.4       Lung NA 
 FId 3 dpi NT 4.6 ± 0.5   FI 3 dpi NT 5.7 ± 0.7 
   Lung 7.3 ± 0.0     Lung 7.1 ± 0.7 
  6 dpi NT 4.0 ± 0.2    6 dpi NT 3.9 ± 0.5 
     Lung 6.0 ± 0.3       Lung 5.3 ± 0.4 
 Once 3 dpi NT 5.2, 5.8   Once 3 dpi NT 4.9 ± 0.4 
   Lung 7.8 ± 0.2     Lung 7.5 ± 0.5 
  6 dpi NT NDe    6 dpi NT 3.3, 3.5 
     Lung 3.4, 3.2       Lung 3.7 ± 2.3 
 Twice 3 dpi NT 4.3, 3.9   Twice 3 dpi NT 6.0  
   Lung 6.1 ± 0.8     Lung 1.6, 6.5 
  6 dpi NT ND    6 dpi NT 1.6 
     Lung 2.5, 2.5       Lung ND 
 
Three 
times 
3 dpi NT ND   
Three 
times 
3 dpi NT ND 
   Lung 2.2     Lung 5.8, 2.4 
  6 dpi NT ND    6 dpi NT ND 
      Lung 2.0         Lung ND 
           
a Twelve mice from each group were intranasally inoculated with 10 or 100 MLD50 of 
mouse-adapted CA04 (50 l per mouse) 3 weeks after the final vaccination. Three mice 
per group were sacrificed on days 3 and 6 post-infection, and lungs and nasal turbinate 
were collected to determine virus titers. Results are expressed as the mean titer (log10 
PFU/g) ±standard deviations. When virus was not recovered from all three mice, 
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individual titers are given. 
b NT: Nasal turbinate 
c NA: Not applicable because the mice died 
d FI: formalin-inactivated virus. Mice were immunized three times with two week 
intervals.  
e ND: Not detected (detection limit, 10 PFU/lung or 5 PFU/NT) 
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Discussion 
 
 Currently, embryonated hen’s eggs are typically used to produce both inactivated 
and live-attenuated vaccines, although cell-based vaccines are approved in Europe. 
However, vaccine production in eggs has several issues. One problem is the alteration of 
antigenicity from that of the circulating virus during cultivation of the vaccine strain in 
embryonated hen’s eggs (Katz et al., 1987; Newman et al., 1993; Williams et al., 1993). 
Another is allergic reactions to components derived from eggs present in vaccines grown 
in eggs (Gruenberg et al., 2011). In contrast, the antigenicity of viruses grown in cells 
closely matches that of viruses isolated from influenza patients (Williams et al., 1993; 
Katz et al., 1989). Since the uncleavable HA virus in this study only grew in HA-
expressing cells and to a level comparable to a virus possessing wild-type HA (Fig. 1), 
production of this vaccine should not only be feasible, but this type of vaccine should 
maintain its antigenicity; however, the cell line needs to be validated to ensure that it is 
free of anything harmful, such as tumorigenicity.  
I demonstrated that antibody responses (IgA and IgG) were efficiently induced 
by the uncleavable HA virus (Fig. 3), like NS2-knockout VLPs (Watanabe et al., 2002). 
In addition to antibody responses, I tested the virus-specific CTL response, which we did 
not examined with our NS2-knockout VLPs, and found that a CTL response to an internal 
viral protein (i.e., NP) was also induced by this virus (Fig. 4). The reason for this induction 
is that viral proteins (NP in this case) are expressed in cells infected with this replication-
incompetent virus, suggesting that this virus could act similarly to a live-attenuated virus 
in terms of induction of immunity despite not generating infectious progeny.  
My findings suggest that a combination of this type of virus and cells expressing 
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a seasonal virus HA can serve as a platform for a bivalent vaccine as follows: If an 
uncleavable H5 HA gene is partnered with the rest of the genes from a seasonal influenza 
virus, the resulting virus can serve as a vaccine against H5 and seasonal influenza viruses. 
That is, antibody responses against H5 HA (expressed from the viral HA gene) and HA 
(derived from the cell line) would likely be induced as would CTL responses against H5 
HA and the internal viral proteins (expressed from the genes of the seasonal virus). 
Likewise, if a gene, encoding a protein responsible for inducing immunity, from another 
respiratory pathogens, such as Streptococcus pneumoniae, which causes secondary 
bacterial infections following influenza virus infection, or respiratory syncytial virus, 
which causes severe manifestations in infants, is inserted into the HA gene, the resultant 
virus may be used as a vaccine against both influenza virus and the other respiratory 
pathogen. 
In conclusion, a replication-incompetent virus that possesses a modified HA 
gene, when partnered with an HA-expressing cell line, has potential as a novel vaccine 
candidate.  
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CHAPTER III 
A bivalent vaccine based on a replication-
incompetent influenza virus protects against 
Streptococcus pneumoniae and influenza virus 
infection.  
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Chapter IIIは雑誌掲載のため公表できません。 
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CONCLUDING REMARKS 
  
Influenza viruses cause epidemics and occasional pandemics. Since the 
beginning of the 20th century, we have experienced four pandemics (Wright et al., 2013). 
In addition, sporadic infections caused by H5N1 and H7N9 viruses have been reported in 
recent years. Despite advances in medicine and the availability of new antivirals, 
influenza viruses continue to be a great threat to our lives. To develop novel antivirals and 
vaccines to control influenza, we must continue to conduct basic research on influenza 
virus infection. In this thesis, I focused on host responses to influenza virus infection and 
novel vaccine production based on genetic recombination technology of influenza virus. 
 In chapter I, I characterized an improved recombinant influenza A virus carrying 
a reporter gene (NS1-Venus PR8 MA virus). I demonstrated that NS1-Venus PR8 MA 
virus stably expressed the Venus protein at high levels. By using NS1-Venus PR8 MA 
virus, I could readily detect virus-infected cells. I believe that NS1-Venus PR8 MA virus 
could be useful not only in intravital live imaging experiments, which has not been 
successful to date, but also in screens for new antivirals.  
 Vaccination is effective in the prophylaxis of influenza virus infection. However, 
there is still room for improvement in the efficacy and safety of our current vaccines. In 
chapter II, I generated a replication-incompetent influenza virus that lacks membrane-
fusion ability to evaluate as an influenza vaccine. I demonstrated that mice inoculated 
with this uncleavable HA virus could successfully elicit not only virus-specific antibodies 
at the surface of respiratory mucosa but also cytotoxic T lymphocytes in the lung. I also 
showed that the uncleavable HA virus completely protected mice from lethal infection 
with influenza virus.  
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 On the basis of the results described in chapter II, in chapter III, I generated a 
bivalent vaccine designed to protect against influenza virus and S. pneumoniae infection. 
By using the packaging signal of the HA segment, I produced HA-KO/PspA virus, which 
expresses PspA protein as an antigen of S. pneumoniae in infected cells. I demonstrated 
that HA-KO/PspA virus could prevent nasal colonization and lethal infection due to S. 
pneumoniae as well as lethal infection by influenza virus. Therefore I believe that a 
replication-incompetent virus can serve as a bivalent vaccine. 
Despite the intense efforts of influenza virus researchers, several important 
problems remain, including the emergence of antiviral-resistant viruses and inefficient 
influenza vaccines. Moreover, we cannot predict which subtype of virus will cause the 
next pandemic. To better understand influenza virus, we must continuously conduct 
intensive basic research. I hope that the results presented here will contribute to the 
elucidation of the pathogenesis of influenza virus and help establish new prophylactic and 
therapeutic measures to control influenza virus infection.  
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